December 11, 2024 07:05 ET | Source: Celcuity Inc. Median overall survival (OS) among patients with HR+, HER2- advanced breast…
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4…
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and…
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease…
December 06, 2024 16:35 ET | Source: BioAge Labs, Inc. Decision follows observations of liver transaminitis without clinically significant symptoms…
December 03, 2024 16:05 ET | Source: Beyond Air™ The Phase 1b study will evaluate LV UNO in unresectable cutaneous…
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each…